FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like Swift Biosciences Doubles Michigan HQ Space And Opens Up Shop In San Francisco October 5, 2017 Sweden's Active Biotech is Strapped for Cash and May Not Survive 2018 December 7, 2017 How Roche Fine-Tuned an Old Drug Under a New Name to Keep Making Profits August 23, 2017
